Telomir制药公司同意购买TELI制药公司,获得全球癌症治疗权和老年药物候选者Telomir-1。 Telomir Pharmaceuticals agreed to acquire TELI Pharmaceuticals, gaining global rights to its cancer and aging drug candidate, Telomir-1.

Telomir制药公司签署了一项获得TELI药品的具有约束力的协议,获得其主要药物候选者Telomir-1(针对癌症、老龄化和与年龄有关的疾病)的全球权利。 Telomir Pharmaceuticals has signed a binding agreement to acquire TELI Pharmaceuticals, gaining worldwide rights to its lead drug candidate, Telomir-1, which targets cancer, aging, and age-related diseases. 该协议将包括美国、欧洲、中国、日本和印度在内的各关键市场的知识产权联合起来,建立了一个单一的全球实体来促进发展。 The deal unites intellectual property across key markets including the U.S., Europe, China, Japan, and India, creating a single global entity to advance development. TELI股东将在独立估值的基础上交换Telomir股票的股份,可能提供的资金可达500万美元,与发展里程碑挂钩。 TELI shareholders will exchange shares for Telomir stock based on an independent valuation, with up to $5 million in potential funding tied to development milestones. Telomir-1在对包括癌症、代谢紊乱和基因老化综合症在内的多种疾病进行临床预科研究方面显示出希望。 Telomir-1 has shown promise in preclinical studies for multiple conditions, including cancers, metabolic disorders, and genetic aging syndromes. 交易正在等待股东批准。 The transaction is pending shareholder approval.